# Features Capital

> Features Capital is a VC fund backing Health Care and Medical Device. See 7 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Norwich, United States
- Total investments: 7
- Last investment: Mar 2025
- Lead investor: 29%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/features-capital/
- Website: https://featuresvc.co/

Features Capital is a VC fund in Norwich focused on Health Care and Medical Device. We invest in and engage teams to create breakthrough solutions that radically transform patient outcomes, improve health economics and bridge health inequities.

## Contacts

5 contacts available for Features Capital. Shizune tracks 1 team members at Features Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/features-capital?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 43% |
| Medical Device | 2 | 29% |
| Wireless | 1 | 14% |
| Biotechnology | 1 | 14% |
| Pharmaceutical | 1 | 14% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 29% |
| Series C | 2 | 29% |
| Series B | 1 | 14% |
| Series D | 1 | 14% |
| Venture - Series Unknown | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 43% |
| Israel | 1 | 14% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Jeff Chu | Co-Founder and Managing Partner | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $100M | Series C | Mar 19, 2025 |  |
| Laplace Interventional | Laplace developing Transcatheter Tricuspid Valve Technology to offer an increase in life expectancy and an improvement to the quality of life to worldwide patients with tricuspid regurgitation. | $22M | Series C | Mar 16, 2025 |  |
| Resonant Link | Resonant Link delivers 5x faster and highly efficient wireless power for applications big to small, from massive industrial trucks to medical devices smaller than a fingernail. Resonant Link’s mission is to provide fast, safe, and reliable wireless power to help people, businesses, and the planet thrive. | $3.4M | Series A | Jan 28, 2025 |  |
| Ocon Healthcare | OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions.In addition to our flagshipproduct, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility. | $10M | Series A | Jun 24, 2024 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M | Venture - Series Unknown | Apr 04, 2024 |  |
| Biolinq | Biolinq is a digital health platform developer that aims to create a pipeline of biomonitoring solutions. The company's platform includes a skin-applied, minimally invasive electrochemical biosensor that analyzes biomarkers in the interstitial fluid to provide actionable health information while continuously monitoring multiple biomarkers,allowing diabetic patients to monitor their blood glucose levels. | $58M | Series D | Apr 04, 2024 |  |
| Laplace Interventional | Laplace developing Transcatheter Tricuspid Valve Technology to offer an increase in life expectancy and an improvement to the quality of life to worldwide patients with tricuspid regurgitation. | $12.9M | Series B | Jul 24, 2023 |  |

7 of 7 investments shown.

## Co-investors
- [Aphelion Capital](https://shizune.co/investors/profile/aphelion-capital) — VC Fund, 4 deals together
- [Alpha Wave Ventures](https://shizune.co/investors/profile/alpha-wave-ventures) — VC Fund, 3 deals together
- [RiverVest](https://shizune.co/investors/profile/rivervest) — VC Fund, 3 deals together
- [Taisho Pharmaceutical Holdings](https://shizune.co/investors/profile/taisho-pharmaceutical-holdings) — VC Fund, 3 deals together
- [AXA Investment Managers](https://shizune.co/investors/profile/axa-investment-managers) — VC Fund, 2 deals together
- Global Health Investment Corporation — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Features Capital invest in?

Features Capital invests primarily in Health Care, Medical Device and Wireless startups, most often at Series A and Series C stage. Most of the 7 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Features Capital?

Public channels for Features Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Features Capital?

The team at Features Capital includes Jeff Chu (Co-Founder and Managing Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co